These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 26971793)
21. MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib. Zheng B; Zhu H; Gu D; Pan X; Qian L; Xue B; Yang D; Zhou J; Shan Y Biochem Biophys Res Commun; 2015 Apr; 459(2):234-239. PubMed ID: 25712526 [TBL] [Abstract][Full Text] [Related]
22. Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. Locatelli SL; Giacomini A; Guidetti A; Cleris L; Mortarini R; Anichini A; Gianni AM; Carlo-Stella C Leukemia; 2013 Aug; 27(8):1677-87. PubMed ID: 23360848 [TBL] [Abstract][Full Text] [Related]
23. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells. Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806 [TBL] [Abstract][Full Text] [Related]
24. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262 [TBL] [Abstract][Full Text] [Related]
25. Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib. Yokoi K; Kobayashi A; Motoyama H; Kitazawa M; Shimizu A; Notake T; Yokoyama T; Matsumura T; Takeoka M; Miyagawa SI Oncol Rep; 2018 Feb; 39(2):843-850. PubMed ID: 29251327 [TBL] [Abstract][Full Text] [Related]
26. Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts. Lin JC; Huang WP; Liu CL; Lee JJ; Liu TP; Ko WC; Huang YC; Hsu ML; Wu CH; Chen YJ Transplantation; 2013 Mar; 95(6):791-800. PubMed ID: 23354299 [TBL] [Abstract][Full Text] [Related]
27. Anti-tumor activities of luteolin and silibinin in glioblastoma cells: overexpression of miR-7-1-3p augmented luteolin and silibinin to inhibit autophagy and induce apoptosis in glioblastoma in vivo. Chakrabarti M; Ray SK Apoptosis; 2016 Mar; 21(3):312-28. PubMed ID: 26573275 [TBL] [Abstract][Full Text] [Related]
28. Autophagy inhibition potentiates SAHA‑mediated apoptosis in glioblastoma cells by accumulation of damaged mitochondria. Lohitesh K; Saini H; Srivastava A; Mukherjee S; Roy A; Chowdhury R Oncol Rep; 2018 Jun; 39(6):2787-2796. PubMed ID: 29658588 [TBL] [Abstract][Full Text] [Related]
29. The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells. Pattarozzi A; Carra E; Favoni RE; Würth R; Marubbi D; Filiberti RA; Mutti L; Florio T; Barbieri F; Daga A Stem Cell Res Ther; 2017 May; 8(1):119. PubMed ID: 28545562 [TBL] [Abstract][Full Text] [Related]
30. Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells. Tuchen M; Wilisch-Neumann A; Daniel EA; Baldauf L; Pachow D; Scholz J; Angenstein F; Stork O; Kirches E; Mawrin C Eur J Cancer; 2017 Mar; 73():9-21. PubMed ID: 28082204 [TBL] [Abstract][Full Text] [Related]
31. Magnolol and honokiol exert a synergistic anti-tumor effect through autophagy and apoptosis in human glioblastomas. Cheng YC; Hueng DY; Huang HY; Chen JY; Chen Y Oncotarget; 2016 May; 7(20):29116-30. PubMed ID: 27074557 [TBL] [Abstract][Full Text] [Related]
32. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer. Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035 [TBL] [Abstract][Full Text] [Related]
33. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531 [TBL] [Abstract][Full Text] [Related]
34. The kinase inhibitor SI113 induces autophagy and synergizes with quinacrine in hindering the growth of human glioblastoma multiforme cells. Matteoni S; Abbruzzese C; Matarrese P; De Luca G; Mileo AM; Miccadei S; Schenone S; Musumeci F; Haas TL; Sette G; Carapella CM; Amato R; Perrotti N; Signore M; Paggi MG J Exp Clin Cancer Res; 2019 May; 38(1):202. PubMed ID: 31101126 [TBL] [Abstract][Full Text] [Related]
35. Chloroquine enhances temozolomide cytotoxicity in malignant gliomas by blocking autophagy. Golden EB; Cho HY; Jahanian A; Hofman FM; Louie SG; Schönthal AH; Chen TC Neurosurg Focus; 2014 Dec; 37(6):E12. PubMed ID: 25434381 [TBL] [Abstract][Full Text] [Related]
36. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro. Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478 [TBL] [Abstract][Full Text] [Related]
37. Sorafenib induces autophagic cell death and apoptosis in hepatic stellate cell through the JNK and Akt signaling pathways. Hao H; Zhang D; Shi J; Wang Y; Chen L; Guo Y; Ma J; Jiang X; Jiang H Anticancer Drugs; 2016 Mar; 27(3):192-203. PubMed ID: 26629768 [TBL] [Abstract][Full Text] [Related]
38. Momelotinib sensitizes glioblastoma cells to temozolomide by enhancement of autophagy via JAK2/STAT3 inhibition. Liu T; Li A; Xu Y; Xin Y Oncol Rep; 2019 Mar; 41(3):1883-1892. PubMed ID: 30664175 [TBL] [Abstract][Full Text] [Related]
39. Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway. Lin MT; Lin CL; Lin TY; Cheng CW; Yang SF; Lin CL; Wu CC; Hsieh YH; Tsai JP Tumour Biol; 2016 May; 37(5):6987-96. PubMed ID: 26662956 [TBL] [Abstract][Full Text] [Related]